BMND8
MCID: BNM022
MIFTS: 42

Bone Mineral Density Quantitative Trait Locus 8 (BMND8)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 8

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 8:

Name: Bone Mineral Density Quantitative Trait Locus 8 56
Osteoporosis 56 71
Osteoporosis, Susceptibility to 56
Bmnd8 56

Classifications:



External Ids:

OMIM 56 611739
UMLS 71 C0029456

Summaries for Bone Mineral Density Quantitative Trait Locus 8

MalaCards based summary : Bone Mineral Density Quantitative Trait Locus 8, also known as osteoporosis, is related to osteoporosis and osteoporosis, juvenile, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Bone Mineral Density Quantitative Trait Locus 8 is BMND8 (Bone Mineral Density Quantiative Trait Locus 8). The drugs Linagliptin and Dinoprostone have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate.

Wikipedia : 74 Bone mineral density quantitative trait locus 8 is a protein that in humans is encoded by the BMND8... more...

More information from OMIM: 611739

Related Diseases for Bone Mineral Density Quantitative Trait Locus 8

Diseases in the Bone Mineral Density Quantitative Trait Locus 15 family:

Bone Mineral Density Quantitative Trait Locus 4 Bone Mineral Density Quantitative Trait Locus 18
Bone Mineral Density Quantitative Trait Locus 1 Bone Mineral Density Quantitative Trait Locus 2
Bone Mineral Density Quantitative Trait Locus 3 Bone Mineral Density Quantitative Trait Locus 5
Bone Mineral Density Quantitative Trait Locus 6 Bone Mineral Density Quantitative Trait Locus 7
Bone Mineral Density Quantitative Trait Locus 8 Bone Mineral Density Quantitative Trait Locus 9
Bone Mineral Density Quantitative Trait Locus 10 Bone Mineral Density Quantitative Trait Locus 11
Bone Mineral Density Quantitative Trait Locus 12 Bone Mineral Density Quantitative Trait Locus 13
Bone Mineral Density Quantitative Trait Locus 14 Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1054)
# Related Disease Score Top Affiliating Genes
1 osteoporosis 13.1
2 osteoporosis, juvenile 12.9
3 osteoporosis-pseudoglioma syndrome 12.8
4 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.7
5 glucocorticoid-induced osteoporosis 12.6
6 juvenile primary osteoporosis 12.6
7 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.6
8 osteoporosis and oculocutaneous hypopigmentation syndrome 12.5
9 hypophosphatemic nephrolithiasis/osteoporosis 12.4
10 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 12.3
11 hajdu-cheney syndrome 12.3
12 growth failure, microcephaly, mental retardation, cataracts, large joint contractures, osteoporosis, cortical dysplasia, and cerebellar atrophy 12.2
13 dominant hypophosphatemia with nephrolithiasis or osteoporosis 12.2
14 bone mineral density quantitative trait locus 15 12.2
15 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 12.2
16 cutis laxa osteoporosis 12.1
17 osteoporosis-macrocephaly-blindness-joint hyperlaxity syndrome 12.1
18 lrp5-related primary osteoporosis 12.1
19 bone mineral density quantitative trait locus 18 12.0
20 bone mineral density quantitative trait locus 16 11.8
21 premature ovarian failure 1 11.7
22 werner syndrome 11.6
23 aromatase deficiency 11.6
24 bone disease 11.6
25 bone mineral density quantitative trait locus 12 11.6
26 rickets 11.6
27 syndromic x-linked intellectual disability snyder type 11.6
28 lysinuric protein intolerance 11.5
29 mental retardation, x-linked, syndromic, snyder-robinson type 11.5
30 geroderma osteodysplasticum 11.5
31 hyperparathyroidism 11.5
32 hypogonadotropic hypogonadism 11.5
33 premature aging syndrome, okamoto type 11.4
34 cerebrotendinous xanthomatosis 11.4
35 acth-secreting pituitary adenoma 11.4
36 cholangitis, primary sclerosing 11.4
37 spondyloocular syndrome 11.4
38 cleidocranial dysplasia 11.4
39 hyperthyroidism 11.4
40 anorexia nervosa 11.4
41 celiac disease 1 11.4
42 systemic mastocytosis 11.4
43 eating disorder 11.3
44 osteopetrosis 11.3
45 multicentric osteolysis, nodulosis, and arthropathy 11.3
46 graves' disease 11.3
47 turner syndrome 11.3
48 severe congenital neutropenia 11.3
49 pituitary adenoma 4, acth-secreting 11.3
50 homocystinuria 11.3

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 8:



Diseases related to Bone Mineral Density Quantitative Trait Locus 8

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 8

Clinical features from OMIM:

611739

UMLS symptoms related to Bone Mineral Density Quantitative Trait Locus 8:


tremor, back pain, angina pectoris, sciatica, equilibration disorder, muscle cramp, pelvic pain

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 8

Drugs for Bone Mineral Density Quantitative Trait Locus 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 599)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4 668270-12-0 10096344
2
Dinoprostone Approved Phase 4 363-24-6 5280360
3
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
4
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
5
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
6
Tibolone Approved, Investigational Phase 4 5630-53-5
7
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
8
Atorvastatin Approved Phase 4 134523-00-5 60823
9
Etanercept Approved, Investigational Phase 4 185243-69-0
10
Acetaminophen Approved Phase 4 103-90-2 1983
11
Pamidronate Approved Phase 4 40391-99-9 4674
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Adalimumab Approved Phase 4 331731-18-1 16219006
14
Montelukast Approved Phase 4 158966-92-8 5281040
15
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
16
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
17
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
18
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
19
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
20
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
21
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
22
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
23
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
24
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
25
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
26
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
27
Gliclazide Approved Phase 4 21187-98-4 3475
28
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
29
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
30
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
31
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
32
Ribavirin Approved Phase 4 36791-04-5 37542
33
Liraglutide Approved Phase 4 204656-20-2 44147092
34
Azathioprine Approved Phase 4 446-86-6 2265
35
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
36
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
37
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
38
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
39
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
40
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
41
Salmon calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
42
Calcium carbonate Approved, Investigational Phase 4 471-34-1
43
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
44
Sodium citrate Approved, Investigational Phase 4 68-04-2
45
Bicalutamide Approved Phase 4 90357-06-5 2375 56069
46
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
47
Goserelin Approved Phase 4 65807-02-5 5311128 47725
48
Cinacalcet Approved Phase 4 226256-56-0 156419
49
Morphine Approved, Investigational Phase 4 57-27-2 5288826
50
Flutamide Approved, Investigational Phase 4 13311-84-7 3397

Interventional clinical trials:

(show top 50) (show all 2182)
# Name Status NCT ID Phase Drugs
1 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
2 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
3 Effect of Mechanical Loading With PTH on Cortical Bone Unknown status NCT03232476 Phase 4
4 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
5 Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research. Unknown status NCT03158246 Phase 4 Generic Zoledronic Acid;Original Zoledronic Acid
6 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
7 Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients Unknown status NCT02156960 Phase 4 Denosumab treatment in osteoporotic patients;Teriparatide treatment in osteoporotic patients;Denosumab and teriparatide treatment in osteoporotic patients
8 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
9 Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
10 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
11 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
12 A Comparative Study of Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty in Patients With Osteoporotic Femoral Neck Fractures Unknown status NCT02148848 Phase 4 Risedronate
13 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
14 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
15 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
16 The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion Unknown status NCT01310465 Phase 4 zoledronic acid;sodium chloride
17 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
18 Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
19 Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures? Unknown status NCT02489825 Phase 4
20 Open Labeled, Propective, Multicentric Phase IV Study to Examine the Influence of Pharmacogenetic Markers on the Efficacy and Side Effects in Postmenopausal, Steroid Hormone Positive Breast Cancer Patients, Who Are Treated With Letrozol. Unknown status NCT01908556 Phase 4 Letrozole
21 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
22 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
23 A Feasibility Study to Explore the Difference in Healing Time Between Teriparatide Treatment and Standard Care on Weber B Ankle Fractures in Older People Unknown status NCT02955056 Phase 4 Forsteo
24 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
25 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
26 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
27 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
28 Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene Completed NCT00079924 Phase 4 teriparatide;aldrenodate;raloxifene
29 Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
30 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
31 Teriparatide Compared With Alendronate on Spine Bone Mineral Density in Postmenopausal Women With Osteoporosis Completed NCT02416271 Phase 4 Teriparatide;Alendronate;Placebo-Oral;Placebo-SC
32 Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis Completed NCT00239629 Phase 4 Teriparatide;Strontium ranelate
33 Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis Completed NCT01544894 Phase 4 Raloxifene;Strontium ranelate
34 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
35 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg Completed NCT00549965 Phase 4 Risedronate Sodium
36 Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis Completed NCT00532545 Phase 4 Teriparatide
37 A One Year, Parallel, Placebo-controlled, Double-blind, Randomized Study to Assess the Effect of Monthly 150mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis Completed NCT02948881 Phase 4 ibandronate
38 A Study of Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene HCl or Placebo Completed NCT00532246 Phase 4 raloxifene;Placebo
39 EVA: Evista Alendronate Comparison Completed NCT00035971 Phase 4 raloxifene HCI and alendronate Na
40 A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients Completed NCT02598934 Phase 4 Ibandronate
41 A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study Completed NCT02598440 Phase 4 Alendronate;Ibandronate
42 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
43 Open Label, Multi-centre, Longitudinal, Prospective, Phase IV Clinical Trial to Compare Two Image Technologies (ImaTx and DXA) Assessing the Anabolic Effects of PTH(1-84) in Postmenopausal Women With Primary Osteoporosis Completed NCT00583518 Phase 4 Parathyroid hormone (PTH)
44 Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study Completed NCT00548509 Phase 4 Menatetrenone (Vitamin K2)
45 An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
46 Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial Completed NCT03005678 Phase 4 Denosumab;Alendronate
47 An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)
48 Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy: a Randomized Double-blind Placebo-controlled Study Completed NCT00371956 Phase 4 raloxifene;placebo
49 A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women Completed NCT00729651 Phase 4 alendronate sodium (+) cholecalciferol;Comparator: Alendronate sodium (Fosamax)
50 Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis Completed NCT01753856 Phase 4 Teriparatide;Denosumab;Demeclocycline;Tetracycline;Calcium Supplement;Vitamin D

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 8

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cholecalciferol
Fluorides
Medium chain triglycerides
MEDRONATE DISODIUM
SODIUM FLUORIDE PWDR

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 8

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 8

MalaCards organs/tissues related to Bone Mineral Density Quantitative Trait Locus 8:

40
Bone, Breast, Prostate, Testes, Kidney, Bone Marrow, Liver

Publications for Bone Mineral Density Quantitative Trait Locus 8

Articles related to Bone Mineral Density Quantitative Trait Locus 8:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Linkage to chromosome 11p12 in two Maltese families with a highly penetrant form of osteoporosis. 61 56
17377523 2007
2
Inhibition of tanshinone IIA on renin activity protected against osteoporosis in diabetic mice. 61
32202179 2020
3
Evaluation of relationship between SPON1 gene and genetic susceptibility of postmenopausal osteoporosis. 61
32484721 2020
4
Bone marrow edema syndrome/transient osteoporosis of the hip joint and management with the utilization of hyperbaric oxygen therapy. 61
32280165 2020
5
Does osteoporosis affect the healing of subcapital humerus and distal radius fractures? 61
32425424 2020
6
Challenges and strategies in management of osteoporosis and fragility fracture care during COVID-19 pandemic. 61
32523258 2020
7
Response to Letter to the Editor: "Risk for Infections During Treatment with Denosumab for Osteoporosis: a Systematic Review and Meta-analysis". 61
32445567 2020
8
Anti-osteoporotic effects of Salvia miltiorrhiza Bunge EtOH extract both in ovariectomized and naturally menopausal mouse models. 61
32311485 2020
9
Extraction, purification and anti-osteoporotic activity of a polysaccharide from Epimedium brevicornum Maxim. in vitro. 61
31751710 2020
10
Novel approach for pathogenesis of osteoporosis in ovariectomized rats as a model of postmenopausal osteoporosis. 61
32339647 2020
11
Serum concentrations of perfluoroalkyl substances and their association with osteoporosis in a population in Jeddah, Saudi Arabia. 61
32485360 2020
12
Letter to the Editor: "Risk for Infections During Treatment With Denosumab for Osteoporosis: a Systematic Review and Meta-Analysis". 61
32445563 2020
13
Liquiritigenin reduces osteoclast activity in zebrafish model of glucocorticoid-induced osteoporosis. 61
32534995 2020
14
ERRATUMERRATUM for "Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis". 61
32516411 2020
15
Expression of Concern: "Menatetrenone (Vitamin K2) and Bone Quality in the Treatment of Postmenopausal Osteoporosis." Nutrition Reviews 2006;64(12):509-517. 61
32412060 2020
16
Establishment of the concurrent experimental model of osteoporosis combined with Alzheimer's disease in rat and the dual-effects of echinacoside and acteoside from Cistanche tubulosa. 61
32278031 2020
17
A patient-level key performance indicator set to measure the effectiveness of fracture liaison services and guide quality improvement: a position paper of the IOF Capture the Fracture Working Group, National Osteoporosis Foundation and Fragility Fracture Network. 61
32266437 2020
18
Dual targeting of SREBP2 and ERRα by carnosic acid suppresses RANKL-mediated osteoclastogenesis and prevents ovariectomy-induced bone loss. 61
31907393 2020
19
Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study. 61
31665462 2020
20
Isoalantolactone inhibits RANKL-induced osteoclast formation via multiple signaling pathways. 61
32388216 2020
21
Bone, inflammation and chronic kidney disease. 61
32275989 2020
22
Nicotinamide mononucleotide attenuates glucocorticoid‑induced osteogenic inhibition by regulating the SIRT1/PGC‑1α signaling pathway. 61
32377728 2020
23
Total hip arthroplasty in patients with osteoporosis. 61
31672068 2020
24
Osteoporosis in the age of COVID-19. 61
32346775 2020
25
Osteoporosis epidemiology using international cohorts. 61
32453035 2020
26
Transient Familial Factor V Leiden-Linked Hip Osteoporosis. 61
32229104 2020
27
Osteoporosis treatment gap in a prospective cohort of volunteer women. 61
32128600 2020
28
Practical guidance for the use of bisphosphonates in osteoporosis. 61
32222607 2020
29
Physically Optimized Nano-Lipid Carriers Augment Raloxifene and Vitamin D Oral Bioavailability in Healthy Humans for Management of Osteoporosis. 61
32194094 2020
30
Raloxifene improves TNF-α-induced osteogenic differentiation inhibition of bone marrow mesenchymal stem cells and alleviates osteoporosis. 61
32550885 2020
31
Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis. 61
32020265 2020
32
Investigation of bone matrix composition, architecture and mechanical properties reflect structure-function relationship of cortical bone in glucocorticoid induced osteoporosis. 61
32224161 2020
33
The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. 61
32234415 2020
34
PSMC6 promotes osteoblast apoptosis through inhibiting PI3K/AKT signaling pathway activation in ovariectomy-induced osteoporosis mouse model. 61
32017075 2020
35
Automatic opportunistic osteoporosis screening using low-dose chest computed tomography scans obtained for lung cancer screening. 61
32072260 2020
36
Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. 61
31628810 2020
37
Synthesis and biological activities of drugs for the treatment of osteoporosis. 61
32335412 2020
38
Bushenhuoxue formula promotes osteogenic differentiation of growth plate chondrocytes through β-catenin-dependent manner during osteoporosis. 61
32334373 2020
39
Abeliophyllum distichum Nakai alleviates postmenopausal osteoporosis in ovariectomized rats and prevents RANKL-induced osteoclastogenesis in vitro. 61
32268206 2020
40
Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment. 61
32020264 2020
41
Network pharmacology approach to elucidate possible action mechanisms of Sinomenii Caulis for treating osteoporosis. 61
32325182 2020
42
Non-coenzyme role of vitamin B1 in RANKL-induced osteoclastogenesis and ovariectomy induced osteoporosis. 61
32100911 2020
43
3'-UTR Polymorphisms of Vitamin B-Related Genes Are Associated with Osteoporosis and Osteoporotic Vertebral Compression Fractures (OVCFs) in Postmenopausal Women. 61
32498429 2020
44
Efficiency of turnip bioactive lipids in treating osteoporosis through activation of Osterix and suppression of Cathepsin K and TNF-α signaling in rats. 61
32253695 2020
45
Preparation and application of polyvinyl alcohol-decorated cell membrane chromatography for screening anti-osteoporosis components from Liuwei Dihuang decoction-containing serum. 61
32135026 2020
46
Testing a theoretical model of imminent fracture risk in elderly women: an observational cohort analysis of the Canadian Multicentre Osteoporosis Study. 61
32034452 2020
47
Comments on Min et al.: Effects of anti-osteoporosis medications on radiological and clinical results after acute osteoporotic spinal fractures: a retrospective analysis of prospectively designed study. 61
32088733 2020
48
Analysis of muscle, hip, and subcutaneous fat in osteoporosis patients with varying degrees of fracture risk using 3T Chemical Shift Encoded MRI. 61
32322608 2020
49
The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. 61
32534221 2020
50
Bioinspired Mineral Hydrogels as Nanocomposite Scaffolds for the Promotion of Osteogenic Marker Expression and the Induction of Bone Regeneration in Osteoporosis. 61
32565370 2020

Variations for Bone Mineral Density Quantitative Trait Locus 8

Expression for Bone Mineral Density Quantitative Trait Locus 8

Search GEO for disease gene expression data for Bone Mineral Density Quantitative Trait Locus 8.

Pathways for Bone Mineral Density Quantitative Trait Locus 8

GO Terms for Bone Mineral Density Quantitative Trait Locus 8

Sources for Bone Mineral Density Quantitative Trait Locus 8

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....